中医药防治慢性肝炎“炎癌转化”的研究进展

余思邈; 王思慈; 郑浩呈; 孙永强; 景婧; 何婷婷; 王丽苹; 张傲哲; 王鑫; 丁霞; 王睿林

doi:10.12449/JCH250926

中医药防治慢性肝炎“炎癌转化”的研究进展

DOI: 10.12449/JCH250926

1.
中国人民解放军总医院第五医学中心中医肝病科，北京 100039
2.
北京中医药大学中医学院，北京 100029

基金项目:

国家自然科学基金面上项目 (81673806);

中国医药教育协会重大科学攻关问题和医药技术难题科研课题 (2020KTY001)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：余思邈负责课题设计及撰写论文；孙永强、景婧、何婷婷、王丽苹、张傲哲、王鑫参与文献搜集与整理；王思慈、郑浩呈协助修改论文；丁霞负责指导撰写及修改文章；王睿林负责拟定写作思路，指导撰写并最后定稿。

详细信息

通信作者:
王睿林， wrl7905@163.com （ORCID： 0000-0002-7129-016X）

计量
- 文章访问数: 137
- HTML全文浏览量: 34
- PDF下载量: 31
- 被引次数: 0
出版历程
- 收稿日期: 2025-03-18
- 录用日期: 2025-06-09
- 出版日期: 2025-09-25

Research advances in traditional Chinese medicine for the prevention and treatment of inflammation-to-cancer transformation in chronic hepatitis

1.
Department of Traditional Chinese Medicine for Liver Disease，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China
2.
School of Traditional Chinese Medicine，Beijing University of Chinese Medicine，Beijing 100029，China

Research funding:

National Natural Science Foundation of China (81673806);

Major Scientific Research Problems and Medical Technology Challenges Project by the Chinese Medical Education Association (2020KTY001)

More Information

Corresponding author: WANG Ruilin， wrl7905@163.com （ORCID： 0000-0002-7129-016X）

摘要

摘要: 原发性肝癌是消化道常见恶性肿瘤之一，慢性肝炎的“炎癌转化”是慢性肝炎向肝癌演进的核心病理过程。慢性肝炎患者因长期存在非可控性炎症反应，导致肝组织反复损伤与修复，逐步发展为肝纤维化、肝硬化，最终通过基因突变及微环境失衡等机制完成恶性转化。慢性肝炎“炎癌转化”是连接慢性肝炎与肝癌的关键环节，其动态演变涉及湿、热、虚、毒、瘀等多种病机因素。其中，湿热与正虚为慢性肝炎“炎癌转化”的始动因素，而瘀毒互结则是推动恶性转化的核心病理产物。中医药基于“治未病”理念，通过多靶点调控炎症、代谢及细胞异常增殖等机制，有效延缓甚至阻断慢性肝炎“炎癌转化”进程，为肝癌防治提供重要策略与研究方向。
- 肝肿瘤 /
- 肝炎，慢性 /
- 中医药学
Abstract: Primary liver cancer is one of the most common malignant tumors of the digestive system， and the “inflammation-to-cancer transformation” （ICT） of chronic hepatitis is the core pathological process of the progression of chronic hepatitis to liver cancer. Persistent and uncontrolled liver inflammation in patients with chronic hepatitis often leads to repeated liver tissue damage and repair， which gradually develops into liver fibrosis and cirrhosis， eventually leading to malignant transformation through the mechanisms such as gene mutation and microenvironment imbalance. ICT in chronic hepatitis is the key link between chronic hepatitis and liver cancer， and its dynamic evolution involves various pathogenic factors such as dampness， heat， deficiency， toxin， and stasis； among which damp-heat and vital energy deficiency are the initiating factors for ICT of chronic hepatitis， while intermingled stasis and toxin are the key pathological products that promote malignant transformation. Based on the concept of preventive treatment， traditional Chinese medicine can effectively delay and even block the ICT of chronic hepatitis by regulating inflammation， metabolism， and abnormal cell proliferation through multiple targets， which provides important strategies and research directions for the prevention and treatment of liver cancer.
- Liver Neoplasms /
- Hepatitis， Chronic /
- Traditional Chinese Medicine and Pharmacy

HTML全文

图 1 慢性肝炎“炎癌转化”核心机制与中医药早期干预示意图

Figure 1. Schematic diagram of the core mechanism of “inflammation and cancer transformation” in chronic hepatitis and early intervention with traditional Chinese medicine

下载: 全尺寸图片幻灯片

参考文献(55)

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
[2]	HANAHAN D, WEINBERG RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144( 5): 646- 674. DOI: 10.1016/j.cell.2011.02.013.
[3]	XU WQ, YU J, WONG VW. Mechanism and prediction of HCC development in HBV infection[J]. Best Pract Res Clin Gastroenterol, 2017, 31( 3): 291- 298. DOI: 10.1016/j.bpg.2017.04.011.
[4]	ZENG HM, CHEN WQ, ZHENG RS, et al. Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6( 5): e555- e567. DOI: 10.1016/S2214-109X(18)30127-X.
[5]	BALKWILL F, MANTOVANI A. Inflammation and cancer: Back to Virchow?[J]. Lancet, 2001, 357( 9255): 539- 545. DOI: 10.1016/S0140-6736(00)04046-0.
[6]	SINGH N, BABY D, RAJGURU J, et al. Inflammation and cancer[J]. Ann Afr Med, 2019, 18( 3): 121. DOI: 10.4103/aam.aam_56_18.
[7]	BARRY AE, BALDEOSINGH R, LAMM R, et al. Hepatic stellate cells and hepatocarcinogenesis[J]. Front Cell Dev Biol, 2020, 8: 709. DOI: 10.3389/fcell.2020.00709.
[8]	HUANG JQ, WU QL, GELLER DA, et al. Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma(HCC)[J]. J Transl Med, 2023, 21( 1): 815. DOI: 10.1186/s12967-023-04716-0.
[9]	WANG SY, HOU J. Research progress on the regulatory mechanism of hepatic inflammation-induced carcinogenesis[J]. Chin J of Cancer Biother, 2020, 27( 1): 1- 8. DOI: 10.3872/j.issn.1007-385x.2020.0. 王素媛, 侯晋. 肝脏炎癌转化调控机制的研究进展[J]. 中国肿瘤生物治疗杂志, 2020, 27( 1): 1- 8. DOI: 10.3872/j.issn.1007-385x.2020.0.
[10]	ZUCMAN-ROSSI J, VILLANUEVA A, NAULT JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149( 5): 1226- 1239. DOI: 10.1053/j.gastro.2015.05.061.
[11]	YU JJ, LING SB, HONG JC, et al. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma[J]. J Immunother Cancer, 2023, 11( 11): e007479. DOI: 10.1136/jitc-2023-007479.
[12]	XU CR, XU Z, ZHANG Y, et al. β-Catenin signaling in hepatocellular carcinoma[J]. J Clin Invest, 2022, 132( 4): e154515. DOI: 10.1172/JCI154515.
[13]	MISHIMA M, TAKAI A, TAKEDA H, et al. TERT upregulation promotes cell proliferation via degradation of p21 and increases carcinogenic potential[J]. J Pathol, 2024, 264( 3): 318- 331. DOI: 10.1002/path.6351.
[14]	NAGARAJU GP, DARIYA B, KASA P, et al. Epigenetics in hepatocellular carcinoma[J]. Semin Cancer Biol, 2022, 86( Pt 3): 622- 632. DOI: 10.1016/j.semcancer.2021.07.017.
[15]	DAI WQ, XU L, YU XN, et al. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism[J]. J Hepatol, 2020, 72( 5): 909- 923. DOI: 10.1016/j.jhep.2019.12.015.
[16]	YAN TL, WANG M, XU Z, et al. Up-regulation of syncytin-1 contributes to TNF-α-enhanced fusion between OSCC and HUVECs partly via Wnt/β-catenin-dependent pathway[J]. Sci Rep, 2017, 7: 40983. DOI: 10.1038/srep40983.
[17]	KOO KY, MOON K, SONG HS, et al. Metabolic regulation by p53: Implications for cancer therapy[J]. Mol Cells, 2025, 48( 4): 100198. DOI: 10.1016/j.mocell.2025.100198.
[18]	TÜMEN D, HEUMANN P, GÜLOW K, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma[J]. Biomedicines, 2022, 10( 12): 3202. DOI: 10.3390/biomedicines10123202.
[19]	YE YA, JIN Q, LI XK, et al. Analysis on the pathogenesis theory of chronic liver disease“depression, deficiency, dampness, toxicity and stasis”[J]. World Chin Med, 2025, 20( 9): 1562- 1566. 叶永安, 靳茜, 李小科, 等. 慢性肝病“郁、虚、湿、毒、瘀”核心病机探讨[J]. 世界中医药, 2025, 20( 9): 1562- 1566.
[20]	YUAN JJ. Research on the etiology, pathogenesis and prevention and treatment strategies of“inflammation-cancer transformation”[D]. Nanjing: Nanjing University of Chinese Medicine, 2016. 袁嘉嘉.“炎-癌转化”的病因病机及防治策略研究[D]. 南京: 南京中医药大学, 2016.
[21]	JIN H. Summary of professor QIAN Ying’s academic thought and clinical experience and theoretical and clinical research on the treatment of compensated stage of hepatitis B liver cirrhosis with the method of harmonizing blood[D]. Beijing: Beijing University of Chinese Medicine, 2016. 靳华. 钱英教授学术思想与临床经验总结及和血法治疗乙肝肝硬化代偿期的理论和临床研究[D]. 北京: 北京中医药大学, 2016.
[22]	MEN QS, LI XL, SUN FX. Application of GUAN Youbo’s theory of“phlegm and stasis” in the treatment of chronic hepatitis B and cirrhosis[J]. Beijing J Tradit Chin Med, 2021, 40( 7): 719- 720. DOI: 10.16025/j.1674-1307.2021.07.008. 门秋爽, 李晓玲, 孙凤霞. 关幼波“痰瘀学说”在慢性乙型肝炎肝硬化治疗中的运用[J]. 北京中医药, 2021, 40( 7): 719- 720. DOI: 10.16025/j.1674-1307.2021.07.008.
[23]	CHEN ST, WU QJ, XU L, et al. Analysis on the evolution of etiology and pathogenesis of chronic hepatitis B virus-related liver disease[J]. Beijing J Tradit Chin Med, 2022, 41( 5): 517- 519. DOI: 10.16025/j.1674-1307.2022.05.013. 陈思童, 武庆娟, 徐蕾, 等. 乙型肝炎病毒相关性慢性肝病的病因病机演变探析[J]. 北京中医药, 2022, 41( 5): 517- 519. DOI: 10.16025/j.1674-1307.2022.05.013.
[24]	YU SM, DING X, LI P, et al. Evolutionary law of syndrome and syndrome elements during the malignant transformation of chronic hepatitis B[J]. J Tradit Chin Med, 2023, 64( 23): 2427- 2434. DOI: 10.13288/j.11-2166/r.2023.23.010. 余思邈, 丁霞, 李萍, 等. 慢性乙型肝炎恶性转化过程证候、证素演变规律的临床研究[J]. 中医杂志, 2023, 64( 23): 2427- 2434. DOI: 10.13288/j.11-2166/r.2023.23.010.
[25]	HE SQ, SUN HT, YANG XM, et al. Qiu Jianxing’s experience in treating chronic hepatitis B based on the damp-heat theory of Lingnan is introduced[J]. J New Chin Med, 2020, 52( 21): 182- 185. DOI: 10.13457/j.cnki.jncm.2020.21.055. 贺松其, 孙海涛, 杨雪梅, 等. 邱健行基于岭南湿热理论辨治慢性乙型肝炎经验介绍[J]. 新中医, 2020, 52( 21): 182- 185. DOI: 10.13457/j.cnki.jncm.2020.21.055.
[26]	TIE SH, YU YX, CHEN YL, et al. Clinical experience of Professor CHEN Siqing in the differentiation and treatment of chronic hepatitis B[J]. Clin J Chin Med, 2023, 15( 33): 59- 61. DOI: 10.3969/j.issn.1674-7860.2023.33.012. 铁生花, 于侑新, 陈亚兰, 等. 陈四清辨治慢性乙肝临证经验撷英[J]. 中医临床研究, 2023, 15( 33): 59- 61. DOI: 10.3969/j.issn.1674-7860.2023.33.012.
[27]	CHENG HB, WU MH. Discussion on academic thought of Professor ZHOU Zhong-ying about cancerous toxin[J]. China J Tradit Chin Med Pharm, 2010, 25( 6): 866- 869. 程海波, 吴勉华. 周仲瑛教授“癌毒”学术思想探析[J]. 中华中医药杂志, 2010, 25( 6): 866- 869.
[28]	CHENG HB, SHEN WX. Relevance of cancer toxin pathogenesis theory with transformation of inflammation to carcinoma[J]. Chin J Integr Tradit West Med, 2015, 35( 2): 243- 246. DOI: 10.7661/CJIM.2015.02.0243. 程海波, 沈卫星. 癌毒病机理论与炎癌转变[J]. 中国中西医结合杂志, 2015, 35( 2): 243- 246. DOI: 10.7661/CJIM.2015.02.0243.
[29]	XIAO HM, SHI MJ, XIE YB, et al. Advances and thoughts in traditional Chinese medicine diagnosis and treatment of chronic hepatitis B-related liver fibrosis[J]. J Clin Hepatol, 2023, 39( 2): 260- 266. DOI: 10.3969/j.issn.1001-5256.2023.02.002. 萧焕明, 施梅姐, 谢玉宝, 等. 慢性乙型肝炎相关肝纤维化中医诊疗进展与思考[J]. 临床肝胆病杂志, 2023, 39( 2): 260- 266. DOI: 10.3969/j.issn.1001-5256.2023.02.002.
[30]	CAI YY. Clinical observation on the treatment of damp-heat type jaundice in chronic hepatitis B with Jiedu Tongli formula combined with western medicine[D]. Guangzhou: Guangzhou University of Chinese Medicine, 2019. 蔡媛媛. 解毒通利方联合西药治疗慢乙肝湿热型黄疸的临床观察[D]. 广州: 广州中医药大学, 2019.
[31]	SU CZ, YANG Q, ZHANG JL, et al. Clinical study on the effect of“clearing turbid regulating liver and invigorating spleen” method on indicators of hepatitis B virus liver cirrhosis[J]. Chin J Integr Tradit West Med Dig, 2024, 32( 2): 115- 119. DOI: 10.3969/j.issn.1671-038X.2024.02.05. 苏春芝, 杨倩, 张金丽, 等.“化浊调肝健脾”法对乙型肝炎病毒相关性肝硬化指标影响的临床研究[J]. 中国中西医结合消化杂志, 2024, 32( 2): 115- 119. DOI: 10.3969/j.issn.1671-038X.2024.02.05.
[32]	JI D, CHEN Y, BI JF, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. J Hepatol, 2022, 77( 6): 1515- 1524. DOI: 10.1016/j.jhep.2022.07.018.
[33]	JIANG SL, FAN HN, LIU P, et al. Current status and review of integrated traditional Chinese and Western medicine diagnosis and treatment of cirrhosis complicated with hepatic carcinoma[J]. Shanghai J Tradit Chin Med, 2023, 57( 8): 21- 26. DOI: 10.16305/j.1007-1334.2023.2304002. 蒋式骊, 范海纳, 刘平, 等. 肝硬化并发肝癌的中西医结合诊治现状与评述[J]. 上海中医药杂志, 2023, 57( 8): 21- 26. DOI: 10.16305/j.1007-1334.2023.2304002.
[34]	XU LL, ZHOU WL, ZHANG SX, et al. Combination of traditional Chinese medicine and antiviral prophylaxis against hepatocarcinogenesis in patients with hepatitis B-related hepatosteatosis[J]. J Math Med, 2021, 34( 6): 878- 880. DOI: 10.3969/j.issn.1004-4337.2021.06.031. 徐兰玲, 周文亮, 张世玺, 等. 中医药联合抗病毒预防乙型肝炎相关性肝硬变患者肝癌发生的相关研究[J]. 数理医药学杂志, 2021, 34( 6): 878- 880. DOI: 10.3969/j.issn.1004-4337.2021.06.031.
[35]	YANG L. A retrospective study on the effect of Bielong soft liver tablets combined with entecavir on the incidence of liver cancer in patients with hepatitis B cirrhosis[D]. Changsha: Hunan University of Chinese Medicine, 2022. 杨亮. 鳖龙软肝片联合恩替卡韦对乙型肝炎肝硬化患者肝癌发生率影响的回顾性研究[D]. 长沙: 湖南中医药大学, 2022.
[36]	CHENG Y, CHEN TY, HE SL, et al. Erzhu Jiedu Decoction in the treatment of hepatitis B cirrhosis with hyperalphafetoproteinemia: A randomized, double-blind and placebo-controlled trial study[J]. Mod J Integr Tradit Chin West Med, 2021, 30( 21): 2290- 2294. DOI: 10.3969/j.issn.1008-8849.2021.21.003. 成扬, 陈天阳, 何胜利, 等. 二术解毒汤治疗乙型肝炎肝硬化伴高甲胎蛋白血症的随机、双盲、安慰剂对照研究[J]. 现代中西医结合杂志, 2021, 30( 21): 2290- 2294. DOI: 10.3969/j.issn.1008-8849.2021.21.003.
[37]	YANG WX, CHEN XS, GONG FY, et al. Effects of fructus broussonetiae on the proliferation, apoptosis and TLR4/NF-κB/TNF-α signal pathway of hepatic stellate cells[J]. Med Sci J Cent South China, 2023, 51( 2): 193- 196. DOI: 10.15972/j.cnki.43-1509/r.2023.02.009. 杨文秀, 陈向穗, 宫凤英, 等. 楮实子对肝星状细胞增殖、凋亡及TLR4/NF-κB/TNF-α信号通路的影响[J]. 中南医学科学杂志, 2023, 51( 2): 193- 196. DOI: 10.15972/j.cnki.43-1509/r.2023.02.009.
[38]	SUN SH, ZHOU XL, LI ZP, et al. Mechanism of modified Chaihu Danggui Decoction in inhibiting fibrosis of hepatic stellate cells based on PI3K/AKT/Bcl-2 signaling pathway[J]. Chin J Gerontol, 2023, 43( 20): 5019- 5023. DOI: 10.3969/j.issn.1005-9202.2023.20.045. 孙素红, 周晓玲, 李泽鹏, 等. 基于PI3K/AKT/Bcl-2信号通路探讨加味柴胡当归汤抑制肝星状细胞纤维化的机制[J]. 中国老年学杂志, 2023, 43( 20): 5019- 5023. DOI: 10.3969/j.issn.1005-9202.2023.20.045.
[39]	ZHAO CS, KONG HB, LI WQ, et al. Effect of bupleurum angelica powder combined with tenofovir alafenamide in the treatment of liver fibrosis in patients with chronic hepatitis B[J]. Clin Misdiagn Misther, 2025, 38( 5): 77- 83. DOI: 10.3969/j.issn.1002-3429.2025.05.015. 赵彩莎, 孔洪彬, 李卫强, 等. 柴胡当归散联合丙酚替诺福韦治疗慢性乙型肝炎肝纤维化的效果观察[J]. 临床误诊误治, 2025, 38( 5): 77- 83. DOI: 10.3969/j.issn.1002-3429.2025.05.015.
[40]	ZHOU WY, XU X, GAO J, et al. TCM matrine inducescell arrest and apoptosis with recovery expression of the hepato-specific miR122a in human hepatocellular carcinomaHep G2cell line[J]. Int J Clin Exp Med, 2015, 8( 6): 9004- 9012.
[41]	GUO W, YAO XH, LAN SY, et al. Metabolomics and integrated network pharmacology analysis reveal SNKAF decoction suppresses cell proliferation and induced cell apoptisis in hepatocellular carcinoma via PI3K/Akt/P53/FoxO signaling axis[J]. Chin Med, 2022, 17( 1): 76. DOI: 10.1186/s13020-022-00628-1.
[42]	LI SN, WANG R, SONG FX, et al. Salvianolic acid A suppresses CCl₄-induced liver fibrosis through regulating the Nrf2/HO-1, NF-κB/IκBα, p38 MAPK, and JAK1/STAT3 signaling pathways[J]. Drug Chem Toxicol, 2023, 46( 2): 304- 313. DOI: 10.1080/01480545.2022.2028822.
[43]	MENG XQ, KUANG HX, WANG QH, et al. A polysaccharide from Codonopsis pilosula roots attenuates carbon tetrachloride-induced liver fibrosis via modulation of TLR4/NF-κB and TGF-β1/Smad3 signaling pathway[J]. Int Immunopharmacol, 2023, 119: 110180. DOI: 10.1016/j.intimp.2023.110180.
[44]	LIU HM, DONG F, LI GQ, et al. Liuweiwuling tablets attenuate BDL-induced hepatic fibrosis via modulation of TGF-β/Smad and NF-κB signaling pathways[J]. J Ethnopharmacol, 2018, 210: 232- 241. DOI: 10.1016/j.jep.2017.08.029.
[45]	YAO CY, WU SL, KONG J, et al. Angiogenesis in hepatocellular carcinoma: Mechanisms and anti-angiogenic therapies[J]. Cancer Biol Med, 2023, 20( 1): 25- 43. DOI: 10.20892/j.issn.2095-3941.2022.0449.
[46]	ZHENG P, HUANG Z, TONG DC, et al. Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways[J]. World J Gastrointest Oncol, 2022, 14( 2): 450- 477. DOI: 10.4251/wjgo.v14.i2.450.
[47]	YANG F, HILAKIVI-CLARKE L, SHAHA A, et al. Metabolic reprogramming and its clinical implication for liver cancer[J]. Hepatology, 2023, 78( 5): 1602- 1624. DOI: 10.1097/HEP.0000000000000005.
[48]	WEI Q, REN Y, ZHENG X, et al. Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway[J]. Bioengineered, 2022, 13( 5): 13919- 13928. DOI: 10.1080/21655979.2022.2074616.
[49]	WU L, YANG FR, XING ML, et al. Multi-material basis and multi-mechanisms of the Dahuang Zhechong pill for regulating Treg/Th1 balance in hepatocellular carcinoma[J]. Phytomedicine, 2022, 100: 154055. DOI: 10.1016/j.phymed.2022.154055.
[50]	HUANG YJ, WANG L, LI S, et al. Effect of mogrol on lipid metabolism of hepatocellular carcinoma HepG2 cells by activating AMPK signaling pathway[J]. Chin J Cancer Biother, 2019, 26( 8): 876- 881. DOI: 10.3872/j.issn.1007-385x.2019.08.008. 黄琰菁, 王琳, 李赛, 等. 罗汉果醇通过激活AMPK信号通路调控肝细胞癌HepG2细胞的脂代谢[J]. 中国肿瘤生物治疗杂志, 2019, 26( 8): 876- 881. DOI: 10.3872/j.issn.1007-385x.2019.08.008.
[51]	WANG S, FU JL, HAO HF, et al. Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy[J]. Pharmacol Res, 2021, 170: 105728. DOI: 10.1016/j.phrs.2021.105728.
[52]	ZHU TT, QI JS, GUO YN, et al. Effect of Fuzheng Huayu prescription on hepatocyte extinction and regeneration in a mouse model of liver cirrhosis[J]. J Clinal Hepatol, 2024, 40( 4): 745- 752. DOI: 10.12449/JCH240417. 朱亭亭, 齐婧姝, 郭亚楠, 等. 扶正化瘀方对肝硬化小鼠模型肝细胞消亡与再生的影响[J]. 临床肝胆病杂志, 2024, 40( 4): 745- 752. DOI: 10.12449/JCH240417.
[53]	ZHAO XL, LI MQ, WANG YH, et al. Exploring the effects of total flavonoids from Carthamus tinctorius Lon hepatic stellate cells based on the Hippo/YAP pathway[J]. J Hainan Med Univ, 2025, 31( 12): 909- 915. DOI: 10.13210/j.cnki.jhmu.20241009.001. 赵晓璐, 李明奇, 王映荷, 等. 基于Hippo/YAP通路探讨红花总黄酮对肝星状细胞活化增殖的作用机制研究[J]. 海南医学院学报, 2025, 31( 12): 909- 915. DOI: 10.13210/j.cnki.jhmu.20241009.001.
[54]	PAN GT, LIU YH, ZHOU FY, et al. Dachengqi decoction protects acute liver injury and systemic inflammatory response by regulating TGF-β1/Smad3 signaling pathway[J]. World Sci Technol-Mod Tradit Chin Med, 2022, 24( 2): 663- 669. DOI: 10.11842/wst.20210824001. 潘广涛, 刘宇寒, 周方园, 等. 大承气汤通过调节TGF-β1/Smad3信号通路减轻大鼠急性肝损伤及全身炎症反应[J]. 世界科学技术-中医药现代化, 2022, 24( 2): 663- 669. DOI: 10.11842/wst.20210824001.
[55]	FAN YH, MAO RF, YANG JH. NF-κB and STAT3 signaling pathways collaboratively link inflammation to cancer[J]. Protein Cell, 2013, 4( 3): 176- 185. DOI: 10.1007/s13238-013-2084-3.